<DOC>
	<DOCNO>NCT02389582</DOCNO>
	<brief_summary>Anticoagulation heparin indicate several situation , acute coronary disease ( combination antiplatelet therapy ) prevention treatment venous thromboembolism situation high risk thromboembolism . Recently , late trial anticoagulation stroke prevention atrial fibrillation show increase risk acute mycardial infarction patient submit new oral anticoagulant , dabigatran . The mechanism still unclear , however , context , previous study interaction anticoagulant ( mainly heparin ) platelet aggregation show conflict result : suggest inhibitory effect heparin platelet function , others suggest heparin could promote increase platelet activation . The present study aim assess effect LMWH Enoxaparin direct thrombin inhibitor , Dabigatran , platelet aggregation , study compare different method patient chronic coronary artery disease ( CAD ) .</brief_summary>
	<brief_title>Effects Low Molecular Weight Heparin Versus Dabigatran Platelet Aggregation Patients With Stable Coronary Artery Disease</brief_title>
	<detailed_description>This prospective open study . We include 29 patient chronic CAD , stable , use ASA . All patient receive medication effective dos recommend stage study , every individual self-control , Enoxaparin administrate dose 1mg/kg twice day Dabigatran dose 150mg twice day . Study Design : Phase 1 : There first collection blood sample patient baseline laboratory test , patient receive Dabigatran 5 day laboratory test include platelet aggregation make , among others . After 30 day washout period , enoxaparin administrate 5 day 6st day , laboratory test , include platelet aggregation , perform .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Age &gt; 18 year old Coronary artery disease , define previous myocardial infarction and/or coronary angioplasty and/or Coronary Artery Bypass Graft ( CABG ) surgery and/or coronariography show obstruction least 50 % one major epicardial vessel Treatment Acetylsalicylic Acid ( ASA ) 100 mg/day Use last 7 day oral anticoagulant antiplatelet drug beside ASA Active bleeding Pregnancy woman childbearing age without contraceptive method Hemoglobin &lt; 10 g/dL hematocrit &lt; 30 % , hematocrit &gt; 50 % , platelet &lt; 100.000/mm3 &gt; 500.000/mm3 ; creatinin clearance &lt; 50 ml/minute Percutaneous coronary intervention ( PCI ) last 30 day randomization ( PCI last year drugeluted stent use ) ; CABG surgery last 90 day ; acute coronary syndrome last 60 day Active malignant neoplasm Active peptic ulcer disease last 60 day upper gastrointestinal bleeding time life Refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>platelet function ; dabigatran ; enoxaparin</keyword>
</DOC>